Download PDF
Thromb Haemost 1999; 82(02): 772-780
DOI: 10.1055/s-0037-1615910
Research Article
Schattauer GmbH

Therapeutic Angiogenesis in Ischemic Heart Disease

Armin Helisch
1   Division of Cardiovascular Medicine, Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA
,
J. Anthony Ware
1   Division of Cardiovascular Medicine, Departments of Medicine and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

    Permissions and Reprints

Introduction

Coronary heart disease is the leading cause of death in the Western world. Traditionally, patients with coronary heart disease requiring a revascularizing procedure have had to undergo either coronary artery bypass surgery, which usually involves open thoracotomy, or percutaneous transluminal balloon angioplasty, or a related procedure. Unfortunately, especially in patients with severe diffuse coronary heart disease, revascularization by these means can be difficult or even impossible. It has been shown that incomplete revascularization is a predictor of a worsened postoperative outcome (i.e., recurrent angina, myocardial infarction, or even death).

We have known for a long time that many patients with ischemic disease develop angiographically visible collateral vessels. Initial research focused on the enlargement of preexisting collateral vessels, a process for which Wolfgang Schaper has proposed the term “neoarteriogenesis.”1 It is now clear that true “angiogenesis,” defined as the formation of new vessels by sprouting from preexisting vessels, also occurs. The latter also should be differentiated from the earliest embryological process of new vessel formation directly from mesodermal endothelial cell precursors, which is called “vasculogenesis.”2

In the last few years, clinical trials have been initiated with the goal of enhancing angiogenesis to treat peripheral vascular disease and ischemic heart disease. In this review, we will summarize the underlying concepts for this novel mode of therapy, plus the available information on its efficacy.

The sprouting of capillaries from preexisting vessels (angiogenesis) is a normal and necessary process to supply the growing organism with nutrients and oxygen. Ischemic vascular disease, along with wound healing and the monthly endometrial proliferation, are conditions in which angiogenesis may be beneficial or necessary. Of course, angiogenesis is also part of the pathogenic mechanism of tumors, hemangiomas, proliferative retinopathies, and inflammatory diseases like rheumatoid arthritis and psoriasis.3 Even in ischemic vascular disease, it is possible that vascularization of atherosclerotic plaques by vessels arising from the vasa vasorum leads to hemorrhages with consequent plaque instability,4 and thus enhancing angiogenesis may promote vessel pathology.

The vasculature of a 70 kg adult is lined by approximately 1,000 m2 of quiescent endothelial cells with a very low turnover rate that can exceed 1,000 days.3 Upon angiogenic activation (e.g., by growth factors released during ischemia), a local inflammatory reaction often can be observed with increased local vascular permeability, vasodilation, and accumulation of monocytes and macrophages. These latter cells release more cytokines and growth factors, which lead to the accumulation of additional inflammatory cells. They also release enzymes that promote the proteolytic degradation of the underlying extracellular matrix and basal membrane. Such degradation causes the endothelial cells to detach from their neighboring cells and the underlying matrix, followed by chemotactic migration and proliferation. Subsequently, formation of a lumen occurs and, eventually, maturation and growth of the newly formed vessel.2,5,6 In vessels larger than capillaries, vascular smooth muscle cells proliferate and migrate as well. In addition, it recently has been shown that circulating endothelial cell precursors released from the bone marrow participate in the formation of new vessels in the setting of tissue ischemia.7 Investigators currently are assessing the importance and contribution of the latter mechanism to neovascularization in the adult organism. If it proves substantial, the traditional means of differentiating between angiogenesis and vasculogenesis may need to be reconsidered.

The regulatory mechanisms of angiogenesis are very complex and only partially understood. Both mechanical factors and multiple endogenous inhibitors have been identified that probably act to inhibit inappropriate endothelial cell proliferation following mitogenic stimulation.3 Most of the known angiogenesis inhibitors circulate in the blood and some have been detected in the matrix around endothelial cells. They include platelet factor 4, thrombospondin-1 and -2, tissue inhibitors of metalloproteinases, and interferon α.3,8 It is unclear whether the endothelium specific inhibitors angiostatin, a 38 kDa fragment of plasminogen,3 and endostatin, a 20 kDa fragment of collagen XVIII,9 are present in physiologically active amounts in organisms without malignant tumors. Of potential importance for myocardial angiogenesis is the recent isolation of an 11 kDa inhibitor of endothelial and smooth muscle proliferation and angiogenesis with homology to the B-cell translocator gene (btg-1) from the bovine heart.1,10 Regarding mechanical factors, contact inhibition of endothelial cell proliferation, which easily can be observed by growing primary endothelial cells in a culture dish, limits excessive endothelial cell growth. Additionally, endothelial cells are surrounded in vivo by a basal lamina, which creates a physical barrier between endothelial cells and the extravascular space. Pericytes may regulate or restrain endothelial cell proliferation. Angiogenesis also can be inhibited by sequestration of angiogenic factors in the extracellular matrix; furthermore, changes of endothelial cell shape may decrease their sensitivity to growth factors.3 On the other hand, many endogenous factors that promote angiogenesis have been identified. These include various growth factors that interact with receptor tyrosine kinases (see below), angiogenin, granulocyte colony stimulating factor, interleukin-8, and proliferin.3,11,12 The balance of these inhibitory and mitogenic influences determines whether angiogenesis occurs.

 

  • References

  • 1 Schaper W, Piek JJ, Munoz-Chapuli R, Wolf C, Ito W. Collateral circulation of the heart. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 159-198.
    Google Scholar
  • 2 Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
    CrossrefPubMedGoogle Scholar
  • 3 Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
    CrossrefPubMedGoogle Scholar
  • 4 Post M, Ware JA. Angiogenesis in Atherosclerosis and Restenosis. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 143-158.
    Google Scholar
  • 5 Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997; 3: 158-164.
    CrossrefPubMedGoogle Scholar
  • 6 Ware JA. Cellular mechanisms of angiogenesis. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 30-59.
    Google Scholar
  • 7 Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
    CrossrefPubMedGoogle Scholar
  • 8 Simons M, Laham RJ. Therapeutic angiogenesis in myocardial ischemia. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 289-320.
    Google Scholar
  • 9 O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
    CrossrefPubMedGoogle Scholar
  • 10 Westernacher D, Schaper W. A novel heart derived inhibitor of vascular cell proliferation. Purification and biological activity. J Mol Cell Cardiol 1995; 27: 1535-1543.
    CrossrefPubMedGoogle Scholar
  • 11 Engleka KA, Maciag T. Molecular mechanisms of the fibroblast growth factor family. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 79-100.
    Google Scholar
  • 12 Ferrara N, Gerber HP. The vascular endothelial growth factor family. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 101-127.
    Google Scholar
  • 13 Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
    CrossrefPubMedGoogle Scholar
  • 14 Bunn FH, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 70: 839-885.
    PubMedGoogle Scholar
  • 15 Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A2 receptors in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 1996; 37: 1311-1321.
    PubMedGoogle Scholar
  • 16 Maltepe E, Schmidt JV, Baunoch D, Bradfeld CA, Simon MC. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997; 386: 403-407.
    CrossrefPubMedGoogle Scholar
  • 17 Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995; 15: 5363-5368.
    CrossrefPubMedGoogle Scholar
  • 18 Wang GL, Jiang B-H, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92: 5510-5514.
    CrossrefPubMedGoogle Scholar
  • 19 Levy AP, Levy NS, Wegner S, Goldberg M. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995; 270: 13333-13340.
    CrossrefPubMedGoogle Scholar
  • 20 Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 1996; 270: H1803-H1811.
    PubMedGoogle Scholar
  • 21 Li J, Hampton T, Morgan JP, Simons M. Stretch-induced VEGF expression in the heart. J Clin Invest 1997; 100: 18-24.
    CrossrefPubMedGoogle Scholar
  • 22 Arras M, Ito WD, Scholz D, Winkler B, Schaper J, Schaper W. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101: 40-50.
    CrossrefPubMedGoogle Scholar
  • 23 Coulier F, Pontarotti P, Roubin R, Hartung H, Goldfarb M, Birnbaum D. Of worms and men: an evolutionary perspective on the fibroblast growth factor (FGF) and FGF receptor families. J Mol Evol 1997; 44: 43-56.
    CrossrefPubMedGoogle Scholar
  • 24 Yu C, English A, Edelman ER. Growth factor delivery strategies. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 238-257.
    Google Scholar
  • 25 Cuevas P, Carceller F, Ortega S, Zazo M, Nieto I, Gimenez-Gallego G. Hypotensive activity of fibroblast growth factor. Science 1991; 254: 1208-1210.
    CrossrefPubMedGoogle Scholar
  • 26 Sellke FW, Harrison DG. Coronary microcirculation and angiogenesis. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 258-288.
    Google Scholar
  • 27 Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625-2634.
    CrossrefPubMedGoogle Scholar
  • 28 Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996; 93: 1493-1495.
    CrossrefPubMedGoogle Scholar
  • 29 Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-7795.
    CrossrefPubMedGoogle Scholar
  • 30 Asahara T, Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Isner JM. A novel function of VEGF: mobilization of bone marrow derived endothelial progenitor cells. Circulation. 1998; 98 (Suppl. 01) 1-605.
    CrossrefPubMedGoogle Scholar
  • 31 Kalka C, Takahashi T, Masuda H, Pieczek A, Asahara T. Intramuscular VEGF gene transfer mobilizes endothelial cell progenitor cells in human subjects. Circulation. 1998; 98 (Suppl. 01) 1-1685.
    CrossrefPubMedGoogle Scholar
  • 32 Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998; 95: 548-553.
    CrossrefPubMedGoogle Scholar
  • 33 Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M, Principe N, Kearney M, Hu JS, Isner JM. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998; 153: 381-394.
    CrossrefPubMedGoogle Scholar
  • 34 Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996; 98: 2507-2511.
    CrossrefPubMedGoogle Scholar
  • 35 Kurz H, Wilting J, Sandau K, Christ B. Automated evaluation of angiogenic effects mediated by VEGF and PlGF homo- and heterodimers. Microvasc Res 1998; 55: 92-102.
    CrossrefPubMedGoogle Scholar
  • 36 Ziche M, Maglione D, Ribatti D, Morbidelli L, Lago CT, Battisti M, Paoletti I, Barra A, Tucci M, Parise G, Vincenti V, Granger HJ, Viglietto G, Persico MG. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest 1997; 76: 517-531.
    PubMedGoogle Scholar
  • 37 Mezaros JG, Brunton LL, Bloor CM. Animal models of angiogenesis in cardiovascular tissues. In: Ware JA, Simons M. eds. Angiogenesis and Cardiovascular Disease. New York: Oxford University Press; 1999: 213-237.
    Google Scholar
  • 38 Michael LH, Entman ML, Hartley CJ, Youker KA, Zhu J, Hall SR, Hawkins HK, Berens K, Ballantyne CM. Myocardial ischemia and reperfusion: a murine model. Am J Physiol 1995; 269: H2147-H2154.
    PubMedGoogle Scholar
  • 39 Couffinhal T, Silver M, Zheng LP, Kearney M, Witzenbichler B, Isner JM. Mouse model of angiogenesis. Am J Pathol 1998; 152: 1667-1679.
    PubMedGoogle Scholar
  • 40 Sanborn TA, Tarazona N, Deutsch E, Lee L, Hackett N, El-Sawy T, Crystal RG. Percutaneous endocardial gene therapy: in vivo gene transfer and expression. J Am Coll Cardiol. 1999; 33 (Suppl A): 262a.
    PubMedGoogle Scholar
  • 41 Arras M, Mollnau H, Strasser R, Wenz R, Ito WD, Schaper J, Schaper W. The delivery of angiogenic factors to the heart by microsphere therapy. Nat Biotechnol 1998; 16: 159-162.
    CrossrefPubMedGoogle Scholar
  • 42 Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R, Epstein SE, Unger EF. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991; 69: 76-85.
    CrossrefPubMedGoogle Scholar
  • 43 Unger EF, Shou M, Sheffield CD, Hodge E, Jaye M, Epstein SE. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am J Physiol 1993; 264: H1567-H1574.
    PubMedGoogle Scholar
  • 44 Unger EF, Banai S, Shou M, Jaklitsch M, Hodge E, Correa R, Jaye M, Epstein SE. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993; 27: 785-791.
    CrossrefPubMedGoogle Scholar
  • 45 Schlaudraff K, Schumacher B, von Specht BU, Seitelberger R, Schlosser V, Fasol R. Growth of “new” coronary vascular structures by angiogenetic growth factors. Eur J Cardiothorac Surg. 1993; 7: 637-643.
    CrossrefPubMedGoogle Scholar
  • 46 Ortega S, Schaeffer MT, Soderman D, DiSalvo J, Linemeyer DL, Gimenez-Gallego G, Thomas KA. Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. J Biol Chem 1991; 266: 5842-5846.
    PubMedGoogle Scholar
  • 47 Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Thomas KA, DiSalvo J, Caputo RP, Carrozza JP, Douglas PS, Sellke FW, Simons M. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol. 1998; 274: H930-H936.
    PubMedGoogle Scholar
  • 48 Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, Sugimoto T, Kaji K, Utsuyama M, Kurashima C. et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992; 257: 1401-1403.
    CrossrefPubMedGoogle Scholar
  • 49 Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura K, Morita T. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J 1995; 130: 1182-1188.
    CrossrefPubMedGoogle Scholar
  • 50 Padua RR, Sethi R, Dhalla NS, Kardami E. Basic fibroblast growth factor is cardioprotective in ischemia- reperfusion injury. Mol Cell Biochem 1995; 143: 129-135.
    CrossrefPubMedGoogle Scholar
  • 51 Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA. bFgf ameliorates focal ischemic injury by blood flow-independent mechanisms in eNos mutant mice. Am J Physiol. 1997; 272: H1401-H1405.
    PubMedGoogle Scholar
  • 52 Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E, Varda-Bloom N, Nass D, Engelberg S, Eldar M. et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22: 2001-2006.
    CrossrefPubMedGoogle Scholar
  • 53 Unger EF, Banai S, Shou M, Lazarous DF, Jaklitsch MT, Scheinowitz M, Correa R, Klingbeil C, Epstein SE. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994; 266: H1588-H1595.
    PubMedGoogle Scholar
  • 54 Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robison Jr. WG, Stiber JA, Correa R, Epstein SE. et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995; 91: 145-153.
    CrossrefPubMedGoogle Scholar
  • 55 Harada K, Grossman W, Friedman M, Edelman ER, Prasad PV, Keighley CS, Manning WJ, Sellke FW, Simons M. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994; 94: 623-630.
    CrossrefPubMedGoogle Scholar
  • 56 Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Caputo RP, Carrozza JP, Douglas PS, Sellke FW, Simons M. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997; 282: 385-390.
    PubMedGoogle Scholar
  • 57 Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992; 16: 181-191.
    CrossrefPubMedGoogle Scholar
  • 58 Pu LQ, Sniderman AD, Brassard R, Lachapelle KJ, Graham AM, Lisbona R, Symes JF. Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 1993; 88: 208-215.
    CrossrefPubMedGoogle Scholar
  • 59 Pu LQ, Sniderman AD, Arekat Z, Graham AM, Brassard R, Symes JF. Angiogenic growth factor and revascularization of the ischemic limb: evaluation in a rabbit model. J Surg Res 1993; 54: 575-583.
    CrossrefPubMedGoogle Scholar
  • 60 Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996; 2: 534-539.
    CrossrefPubMedGoogle Scholar
  • 61 Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N, Isner JM, Symes JF. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994; 90 II 228-234.
    PubMedGoogle Scholar
  • 62 Takeshita S, Zheng LP, Brogi E, Kearney M, Pu LQ, Bunting S, Ferrara N, Symes JF, Isner JM. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 1994; 93: 662-670.
    CrossrefPubMedGoogle Scholar
  • 63 Bauters C, Asahara T, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM. Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factor. J Vasc Surg 1995; 21: 314-324.
    CrossrefPubMedGoogle Scholar
  • 64 Takeshita S, Tsurumi Y, Couffinahl T, Asahara T, Bauters C, Symes J, Ferrara N, Isner JM. Gene transfer of naked DNA encoding for three isoforms of vascular endothelial growth factor stimulates collateral development in vivo. Lab Invest 1996; 75: 487-501.
    PubMedGoogle Scholar
  • 65 Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Unger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994; 89: 2183-2189.
    CrossrefPubMedGoogle Scholar
  • 66 Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, Stiber JA, Lobo AD, Hunsberger S, Guetta E, Epstein SE, Unger EF. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996; 94: 1074-1082.
    CrossrefPubMedGoogle Scholar
  • 67 Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV, Pearlman JD, Edelman ER, Sellke FW, Simons M. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996; 270: H1791-H1802.
    PubMedGoogle Scholar
  • 68 Sayeed-Shah U, Mann MJ, Martin J, Grachev S, Reimold S, Laurence R, Dzau V, Cohn LH. Complete reversal of ischemic wall motion abnormalities by combined use of gene therapy with transmyocardial laser revascularization. J Thorac Cardiovasc Surg 1998; 116: 763-769.
    CrossrefPubMedGoogle Scholar
  • 69 Nakamura S, Moriguchi A, Nakamura Y, Mastsushita H, Aoki M, Tomita N, Nakamura T. Therapeutic angiogenesis by a single intra-arterial injection of human hepatocyte growth factor (HGF) in rabbit ischemic hind limb model as “supplement cytokine therapy.”. Circulation 1998; 98 (Suppl. 01) 1-268.
    CrossrefPubMedGoogle Scholar
  • 70 Shyu K-G, Vincent KA, Luo Y, Magner M, Tio RA, Jiang C, Akita GY, Isner JM, Gregory RJ. Naked DNA encoding an hypoxia-inducible factor 1α (HIF-1α)/VP16 hybrid transcription factor enhances angiogenesis in rabbit hindlimb ischemia: an alternate method for therapeutic angiogenesis utilizing a transcriptional regulatory system. Circulation. 1998; 98 (Suppl. 01) 1-68.
    CrossrefPubMedGoogle Scholar
  • 71 Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97: 645-650.
    CrossrefPubMedGoogle Scholar
  • 72 Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann Thorac Surg 1998; 65: 1540-1544.
    CrossrefPubMedGoogle Scholar
  • 73 Laham RJ, Sellke FW, Ware JA, Pearlman JD, Edelman ER, Simons M. Results of a randomized, double-blind, placebo-controlled study of local perivascular basic fibroblast growth factor (bFGF) treatment in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 1999; 33 (Suppl A) 383A-384a.
    PubMedGoogle Scholar
  • 74 Laham RJ, Leimbach M, Chronos NA, Vansant JP, Pearlman JD, Pettigrew R, Guler H-P, Whitehouse MJ, Hung D, Baim DS, King III SB, Simons M. Intracoronary administration of recombinant fibroblast growth factor-2 (rFGF-2) in patients with severe coronary artery disease: results of phase I. J Am Coll Cardiol. 1999; 33 (Suppl A): 383a.
    PubMedGoogle Scholar
  • 75 Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, Ashare AB, Lathi K, Isner JM. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804.
    CrossrefPubMedGoogle Scholar
  • 76 Vale PR, Losordo DW, Dunnington CH, Lathi K, Esakof DD, Symes JF, Isner JM. Direct intramyocardial injection of VEGF results in effective gene transfer for patients with chronic myocardial ischemia. J Am Coll Cardiol. 1999; 33 (Suppl A): 384a.
    PubMedGoogle Scholar
  • 77 Rosengart TK, Patel SR, Lee LY, Sanborn TA, Hachamovitch R, Kligfield PD, Isom OW, Crystal RG. Safety of direct myocardial VEGF121 cDNA adenovirus-mediated angiogenesis gene therapy in conjunction with coronary bypass surgery. Circulation. 1998; 98 (Suppl. 01) 1-321.
    CrossrefPubMedGoogle Scholar
  • 78 Henry TD, Annex BH, Azrin MA, McKendall GR, Willerson JT, Hendel RC, Giordano F, Klein R, Gibson M, Berman DS, Luce CA, McCluskey ER. Double blind, placebo controlled trial of recombinant human vascular endothelial growth factor - the VIVA trial. J Am Coll Cardiol. 1999; 33 (Suppl.A): 384a.
    PubMedGoogle Scholar